Klinische Forschung Berlin-Mitte GmbH

The site is conducting studies on atherosclerotic cardiovascular disease, atrial fibrillation, and elevated lipoprotein(a) to evaluate new treatments that aim to lower the risk of heart attacks and strokes.

• Risk reduction in patients with atrial fibrillation unsuitable for anticoagulation
• Lipoprotein(a) lowering agents
• Therapies targeting major adverse cardiovascular events

These trials support the development of innovative cardiovascular therapies and involve a multidisciplinary team at the Berlin research facility.

Research focuses on conditions such as ulcerative colitis, irritable bowel syndrome, and celiac disease, with the goal of improving symptom control and intestinal health.

• Evaluation of novel agents for ulcerative colitis remission
• Therapies for diarrhoea‑predominant irritable bowel syndrome
• Adjunct treatments for non‑responsive celiac disease

The studies aim to enhance quality of life for patients with chronic gastrointestinal disorders.

Investigations include female androgenetic alopecia, a condition linked to hormonal imbalance, testing new oral and topical treatments to promote hair growth.

• Combination oral minoxidil and topical therapy
• Comparison with standard minoxidil formulations

Results will inform therapeutic options for hormone‑related hair loss at Klinische Forschung Berlin‑Mitte GmbH.

Studies address autoimmune and inflammatory conditions such as ulcerative colitis and celiac disease, aiming to modulate immune responses and reduce disease activity.

• Targeted biologic agents for ulcerative colitis
• Immunomodulatory therapy for celiac disease

The research seeks to advance immune‑focused treatments for chronic inflammatory diseases.

Clinical work includes osteoarthritis and chronic low back pain, evaluating pain‑relieving compounds and weight‑loss interventions that may alleviate joint stress.

• Pain reduction in chronic low back pain
• Weight‑loss agents for overweight patients with osteoarthritis

These projects aim to improve mobility and reduce reliance on opioid medications.

Research targets cognitive impairment following COVID‑19 and other neurological sequelae, testing herbal extracts and other agents to support brain function.

• Ginkgo biloba extract for post‑COVID cognitive deficits
• Assessment of safety and efficacy in neurocognitive outcomes

The goal is to identify supportive therapies that enhance recovery of neurological health.

Trials focus on obesity, hyperlipidemia, and metabolic syndrome, investigating novel oral agents that aim to reduce body weight and improve lipid profiles.

• Weight‑loss medication evaluated for body‑mass reduction
• LDL‑cholesterol lowering treatment in high‑risk patients
• Therapies targeting elevated lipoprotein(a)

Outcomes will contribute to strategies for managing metabolic health at the Berlin site.

The programme includes studies on chronic obstructive pulmonary disease, refractory chronic cough, and respiratory syncytial virus, aiming to develop treatments that improve breathing and prevent infections.

• Bronchodilator and anti‑cough agents for chronic cough
• Vaccines targeting RSV and hMPV in older adults
• Therapeutic options for COPD management

These efforts support better respiratory outcomes for diverse patient populations.

Research includes conditions affecting skin and connective tissue, exploring therapies that may modulate inflammation and improve tissue integrity.

• Investigational agents for inflammatory skin disorders
• Studies on connective tissue health in systemic diseases

The work aims to broaden therapeutic options for dermatologic and connective‑tissue conditions.

Ongoing investigations evaluate influenza vaccines and novel mRNA platforms to enhance protection against seasonal viruses.

• Safety and immunogenicity of a new influenza mRNA vaccine
• Comparative effectiveness against standard influenza vaccines

These studies contribute to public health preparedness and vaccine innovation.

A broad portfolio addresses major depressive disorder, anxiety, and attention‑deficit/hyperactivity disorder, testing novel pharmacologic agents and adjunctive therapies to improve mental health outcomes.

• Kappa‑opioid receptor antagonist for depression
• Adjunctive aticaprant for relapse prevention
• Dexamphetamine formulations for adult ADHD
• Essential oil preparation for mild to moderate depression

The trials seek to expand effective treatment options for patients with mood and attention disorders.

Studies explore sleep disturbances and insomnia, evaluating new sleep‑inducing compounds to enhance restorative rest.

• Efficacy of a novel agent for insomnia disorder

Improved sleep quality is expected to benefit overall psychological well‑being.